5 Best Jim Cramer Stocks to Watch in December

In this article, we discuss the 5 best stocks to watch in December according to Jim Cramer. If you want to read our detailed analysis of these stocks, go directly to 10 Best Jim Cramer Stocks to Watch in December.

5. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 44

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biotech company that is based in New York, is one of the stocks Jim Cramer is watching in December. The company develops RNA-based therapies for chronic diseases. During his Mad Money episode aired on December 10, Cramer stated that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a profitable biotech company that trades at a very low price.

Meanwhile, the biotech company recently reported positive Phase 3 clinical data on its lead drug Dupixent. The study found that Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) Dupixent significantly improved skin clearance and reduced overall disease severity and itch in infants and children with severe atopic dermatitis aged 6 months to 5 years. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock has risen 37% year to date.

On December 8, Wells Fargo analyst Mohit Bansal initiated an Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a price target of $750 per share. Overall, 44 hedge funds tracked by Insider Monkey were long Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at the end of the third quarter of 2021.

Here is what Oakmark Funds has to say about Regeneron Pharmaceuticals, Inc. in its Q2 2021 investor letter:

“We restored Regeneron Pharmaceuticals from a rather trivial to a more normal position size. You may recall Regeneron performed well for the Fund during the Covid-19 crisis, so we significantly reduced our position as its price-value gap narrowed. During the past several quarters, however, the market has experienced the now infamous “reopening trade,” in which companies that performed well during the pandemic trailed as the economy reopened. Regeneron suffered a similar fate and its shares have lagged the S&P 500 by roughly 4000 basis points, despite the company’s strong fundamentals and robust pipeline of new products. The underperformance widened Regeneron’s price-value gap, so we restored it to a more normal position size.”